Compare Novartis with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DISHMAN PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DISHMAN PHARMA NOVARTIS/
DISHMAN PHARMA
 
P/E (TTM) x 496.6 25.1 1,979.1% View Chart
P/BV x 28.8 3.3 860.6% View Chart
Dividend Yield % 1.6 0.7 238.9%  

Financials

 NOVARTIS   DISHMAN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
DISHMAN PHARMA
Mar-16
NOVARTIS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs758374 202.5%   
Low Rs579129 449.2%   
Sales per share (Unadj.) Rs228.4197.8 115.5%  
Earnings per share (Unadj.) Rs31.721.2 149.7%  
Cash flow per share (Unadj.) Rs32.834.7 94.4%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.8 188.2%  
Book value per share (Unadj.) Rs297.1179.9 165.2%  
Shares outstanding (eoy) m24.6980.69 30.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.3 230.1%   
Avg P/E ratio x21.111.9 177.5%  
P/CF ratio (eoy) x20.47.2 281.5%  
Price / Book Value ratio x2.21.4 160.8%  
Dividend payout %31.59.4 334.1%   
Avg Mkt Cap Rs m16,50520,306 81.3%   
No. of employees `0000.70.8 80.6%   
Total wages/salary Rs m1,4455,355 27.0%   
Avg. sales/employee Rs Th8,441.319,252.7 43.8%   
Avg. wages/employee Rs Th2,163.66,459.5 33.5%   
Avg. net profit/employee Rs Th1,173.12,064.1 56.8%   
INCOME DATA
Net Sales Rs m5,63915,961 35.3%  
Other income Rs m1,718265 647.4%   
Total revenues Rs m7,35716,226 45.3%   
Gross profit Rs m-634,103 -1.5%  
Depreciation Rs m251,091 2.3%   
Interest Rs m55944 5.9%   
Profit before tax Rs m1,5752,334 67.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792624 126.9%   
Profit after tax Rs m7841,711 45.8%  
Gross profit margin %-1.125.7 -4.3%  
Effective tax rate %50.326.7 188.1%   
Net profit margin %13.910.7 129.6%  
BALANCE SHEET DATA
Current assets Rs m9,52211,018 86.4%   
Current liabilities Rs m3,2969,517 34.6%   
Net working cap to sales %110.49.4 1,174.0%  
Current ratio x2.91.2 249.5%  
Inventory Days Days37110 33.1%  
Debtors Days Days2835 81.6%  
Net fixed assets Rs m4616,304 0.3%   
Share capital Rs m123161 76.5%   
"Free" reserves Rs m7,21312,907 55.9%   
Net worth Rs m7,33614,516 50.5%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m11,10529,805 37.3%  
Interest coverage x29.53.5 849.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.5 94.8%   
Return on assets %7.68.9 84.8%  
Return on equity %10.711.8 90.6%  
Return on capital %22.217.5 126.8%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m614,952 1.2%   
Fx outflow Rs m3,630697 521.0%   
Net fx Rs m-3,5704,255 -83.9%   
CASH FLOW
From Operations Rs m1,6102,786 57.8%  
From Investments Rs m687-1,529 -44.9%  
From Financial Activity Rs m-2,677-941 284.4%  
Net Cashflow Rs m-380316 -120.0%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 3.7 54.1%  
FIIs % 1.6 12.7 12.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 22.1 97.3%  
Shareholders   41,647 46,261 90.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS